On October 1, Liquidia Technologies Inc fell 23.6% in regular trading, trading at $23.515 per share, with turnover of $83.1186 million. The sharp decline follows a patent litigation ruling that went against the company, severely undermining market confidence in its commercial outlook.

According to public information, Liquidia lost a key patent lawsuit, raising the risk that its core product YUTREPIA — an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) — could face patent infringement damages or restrictions on its market availability. The ruling has directly disrupted expectations for sustained volume growth of the product, which is central to the company's revenue trajectory.

Liquidia Corporation is a biopharmaceutical company headquartered in Morrisville, North Carolina, leveraging its proprietary PRINT particle engineering technology platform for drug development and manufacturing. Beyond YUTREPIA, the company also offers Remodulin and holds a license agreement for L606, an inhaled sustained-release treprostinil formulation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)